Skip to main content

Table 6 Results of univariate and multivariate analysis of factors associated with PFS

From: Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor

Parameters

Univeriate analysis #

 

Multiveriate analysis

HR

(95%CI)

P Value

HR

(95%CI)

P Value

CRAFITY score

2.412

1.618–3.595

< 0.001

 

2.279

1.454–3.571

< 0.001

Age

1.004

0.981–1.027

0.739

    

Gender

1.076

0.525–2.203

0.841

    

Pathogeny

0.895

0.487–1.645

0.720

    

ECOG score

1.046

0.594–1.840

0.876

    

Child-Pugh class

0.963

0.451–2.056

0.922

    

ALT

1.005

0.995–1.016

0.325

 

0.996

0.982–1.010

0.553

AST

1.003

1.000-1.007

0.072

 

1.003

0.997–1.009

0.342

PLR

1.004

1.001–1.006

0.013

 

1.000

0.995–1.004

0.985-

NLR

1.057

0.963–1.161

0.244

 

1.022

0.900–1.160

0.739

Types of TKIs

0.996

0.720–1.377

0.980

    

TACE sessions

1.031

0.928–1.146

0.564

    

BCLC stage

1.529

0.872–2.680

0.138

 

1.017

0.542–1.907

0.959

Tumor number

1.085

0.820–1.437

0.568

    

Tumor size

1.433

0.928–2.213

0.105

 

1.287

0.777–2.133

0.328

  1. # variables with P value ≤ 0.4 in the univariate analysis were further included in the multivariate Cox proportional hazards regression model analysis. PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group ALT, alanine aminotransferase; AST, aspartate aminotransferase; PLR, platelet/lymphocyte ratio; NLR, neutrophil/lymphocyte ratio; TKIs, tyrosine kinase inhibitors; TACE, transarterial chemoembolization; BCLC Barcelona Clinic Liver Cancer
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us